Valuation: Vector Science and Therapeutics Corp.

Market Cap 242M 216M 202M 183M 346M 23.46B 348M 2.43B 947M 11.93B 910M 891M 38.31B P/E 2024 *
-
P/E 2025 -0.29x
Enterprise Value 240M 214M 200M 181M 342M 23.18B 344M 2.4B 936M 11.79B 900M 880M 37.86B EV / Sales 2024 *
-
EV / Sales 2025 -
Free-Float
79.73%
Yield 2024 *
-
Yield 2025 -
08-24 Vector Science Starts Manufacturing Pharma-Grade Peptides MT
08-24 Vector Science & Therapeutics Increases Peptide Manufacturing Capacity At Lyogenesis Facility CI
08-24 Vector Science & Therapeutics Begins Peptide Production As First Suite At LyoGenesis Manufacturing Comes Online CI
08-20 Vector Science and Therapeutics Corp Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides CI
08-17 Vector Science and Therapeutics Signs Amended 10-Year Manufacturing and Testing Agreement MT
08-17 Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement With LyoGenesis Holdings LLC CI
07-28 Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products CI
07-24 Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026 CI
07-21 Vector Science to Build Distributor Network For Peptide Portfolio Commercialization MT
07-17 Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist CI
07-17 Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax MT
07-15 Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery CI
07-08 Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board CI
1 day+1.14%
1 week-7.33%
Current month-7.33%
1 month-5.85%
3 months-27.76%
6 months+378.38%
Current year+3,440.00%
1 week 1.65
Extreme 1.65
2.03
1 month 1.65
Extreme 1.65
2.15
Current year 0.35
Extreme 0.35
2.65
1 year 0.35
Extreme 0.35
2.65
3 years 0.03
Extreme 0.03
2.65
5 years 0.03
Extreme 0.03
2.65
10 years 0.03
Extreme 0.03
2.65
Date Insider Type Main position Quantity % Market Cap. Importance
25/09/26 Option

Chief Financial Officer

150,000 0.1562%
28/08/26 Sell

Director

-125,000 0.1302%
13/07/26 Buy

Director

2,000 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+1.14%-7.33%+378.38%+5,800.00% 192M
-0.89%+0.28%+31.50%+89.70% 125B
-3.61%-5.23%+33.70%+78.58% 22.62B
-0.98%-1.82%+20.21%+48.71% 16.62B
+0.85%-2.11%+14.55%+143.26% 15.62B
-1.83%-2.93%+12.82%+23.25% 14.24B
-0.58%+2.67%+69.99%+97.71% 13.72B
-1.22%-0.05%-12.59%+6.32% 13.1B
+0.24%-1.31%-10.99%+55.75% 12.26B
+0.77%-3.66%+21.56%+37.71% 12.1B
Average -0.61%-1.22%+55.91%+638.10% 24.57B
Weighted average by Cap. -0.95%-0.13%+26.24%+81.67%

Financials

*1 *
Net sales - -
Net income - -
Net Debt - -
Projected Income Statement - Annual - Vector Science and Therapeutics Corp.
Logo Vector Science and Therapeutics Corp.
Vector Science and Therapeutics Corp. is a Canada-based company. The Company develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions. The Company's product platforms and applications include Laparoscopic Atomizing Solution System (LASS) and Biomechanical Transdermal Device (BTP). The LASS Platform is an atomizing solution system designed to deliver therapeutics/anesthetics in a manner that infiltrates tissue to have a specific therapeutic effect. VectorMist is a catheter-based system designed for targeted delivery of atomized therapeutics directly into the surgical field during laparoscopic procedures. Vector BTP is an electrical biomechanical platform that functions as both a standalone therapeutic intervention and a drug delivery platform competing directly with sustained acoustic medicine devices and pulsed electromagnetic field devices in the regenerative and sports medicine segments.
Employees
-
Date Price Change Volume
07/10/26 CA$1.770 +1.14% 24,074
06/10/26 CA$1.750 -7.89% 276,081
05/10/26 CA$1.900 +0.53% 201,826
02/10/26 CA$1.890 -6.90% 24,479
01/10/26 CA$2.030 +6.28% 590,771
  1. Stock Market
  2. Stocks
  3. PAIN Stock